|POZEN To Present at the Oppenheimer Conference ''Positioning Investors for the Next Wave in Pain Management''|
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 28, 2007--POZEN Inc. (NASDAQ: POZN) announced today that Marshall E. Reese, Ph.D., the company's executive vice president, product development, will participate in the "Current Treatments for Pain Management" panel at the Oppenheimer "Positioning Investors For The Next Wave In Pain Management" Conference on Tuesday, March 6, 2007 at 8:30 a.m. (ET) at the Flatotel in New York City.
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Trexima(TM) combining sumatriptan, formulated with RT Technology(TM), and naproxen sodium in a single tablet for the acute treatment of migraine, which is currently under review by the United States Food and Drug Administration; and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.